+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer



Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer



Laboratory Investigation; A Journal of Technical Methods and Pathology 77(4): 345-355



Matrix metalloprotease-9 (MMP-9; 92-kd type IV collagenase, gelatinase B) is regarded as important for degradation of the basement membrane and extracellular matrix during cancer invasion and other tissue-remodeling events. Expression of MMP-9 was analyzed in 22 cases of human ductal breast cancer by immunohistochemistry and in 8 of these cases also by in situ hybridization. For immunohistochemistry we used affinity-purified polyclonal antibodies as well as a MMP-9-specific monoclonal antibody (clone 6-6B). Three different stromal cell types with a positive MMP-9 immunoreaction were identified morphologically: neutrophils and macrophage-like cells in all cases and vascular cells in 16 of 22 cases. Double immunofluorescence with antibodies to CD68 conclusively demonstrated MMP-9 expression in macrophages. To identify the positive vascular cells, we employed antibodies to von Willebrand factor and PAL-E for identification of endothelial cells, high molecular weight melanoma-associated antigen for pericytes, and alpha-smooth muscle actin for vascular smooth muscle cells. Using conventional and confocal double immunofluorescence microscopy, colocalization of MMP-9 was seen with high molecular weight melanoma-associated antigen, the pericyte marker, whereas little or no coexpression was seen with alpha-smooth muscle actin. Virtually no coexpression was seen with the endothelial cell markers PAL-E and von Willebrand factor. In situ hybridization showed that MMP-9 mRNA colocalized with MMP-9 immunoreactivity in macrophages and vascular structures, whereas no MMP-9 mRNA was detected in neutrophils. No MMP-9 immunostaining or in situ hybridization signal was detected in cancer cells in any of the cases. Based on these results, it is concluded that MMP-9 in human breast cancer is located in tumor-infiltrating stromal cells, including neutrophils, macrophages, and vascular pericytes, and that the latter two cell types also produce this metalloprotease. We suggest that the MMP-9 produced in pericytes may play a role in extracellular matrix degradation during tumor angiogenesis.

(PDF emailed within 1 workday: $29.90)

Accession: 008661985

Download citation: RISBibTeXText

PMID: 9354769


Related references

High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma. Pancreas 45(7): 1067-1072, 2017

Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. Breast Cancer Research & Treatment 68(3): 225-237, 2001

Expression of matrix metalloprotease and tissue inhibitor of metalloprotease genes in human anterior cruciate ligament. Journal of Orthopaedic Research 19(4): 642-649, 2001

PPARgammain human vascular smooth muscle cells Inhibition of matrix metalloprotease expression, activity, and cell migration. Circulation 98(17 SUPPL ): I382-I383, Oct 27, 1998

HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR. Anticancer Research 27(4b): 2265-2268, 2007

The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. Journal of Biological Chemistry 287(29): 24631-24640, 2012

Correspondence re N-B Liabakk et al, matrix metalloprotease 2 and matrix metalloprotease 9 type IV collagenases in colorectal cancer Cancer Res, 56 190-196, 1996. Cancer Research 56(15): 3610, 1996

Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specificities. Journal of Molecular Modeling 3(1): 17-30, 1997

Immunohistochemical expression of matrix metalloprotease-2 and matrix metalloprotease-9 in the disks of patients with temporomandibular joint dysfunction. Journal of Oral Pathology and Medicine 44(1): 75-79, 2016

Role of NF-κB activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells. Cell Biochemistry and Function 31(3): 263-268, 2013

Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. Bmc Cancer 12: 47, 2012

Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice. Neoplasia 11(10): 1106-1115, 2010

Systemic Sclerosis-Endothelial Cell Antiangiogenic Pentraxin 3 and Matrix Metalloprotease 12 Control Human Breast Cancer Tumor Vascularization and Development in Mice. Neoplasia 11(10): 1106-1115, 2009

Alternagin-C binding to α 2 β 1 integrin controls matrix metalloprotease-9 and matrix metalloprotease-2 in breast tumor cells and endothelial cells. Journal of Venomous Animals and Toxins Including Tropical Diseases 24: 13, 2018

Matrix metalloprotease 2 and matrix metalloprotease 9 type IV collagenases in colorectal cancer. Cancer Research 56(1): 190-196, 1996